Gland Pharma has signed a large manufacturing agreement with a global partner for 55 injectable product lines, with peak annual revenue estimated at $90-100 million starting in 2029. This development follows a strong first quarter for the company, where profit jumped 47% year-on-year. Investors are now tracking how the company manages the complex two-year technology transfer process.
Gland Pharma has confirmed a major contract manufacturing deal with a large global pharmaceutical company. The agreement covers the production of 55 different injectable product items. It is expected to add $90 million to $100 million in annual revenue once fully operational. While the deal is a significant win for long-term growth, the company expects commercial production to begin in 2029, as the project involves a two-year technology transfer phase before full manufacturing can start.
The company’s recent performance provides context for this optimism. In the first quarter of the 2027 fiscal year, Gland Pharma reported revenue of Rs 18 billion, a 19.6% increase compared to the same period last year. Profitability also improved significantly, with EBITDA reaching Rs 4.89 billion and Profit After Tax rising 47% to Rs 3.17 billion. The company’s operating profit margin reached 27.2% during this quarter, up from 24.4% a year ago.
This agreement highlights Gland Pharma’s strategic shift toward contract development and manufacturing, commonly known as CDMO. This segment has become a core pillar of the business, now contributing about half of the company's total revenue. By taking on projects for other large pharmaceutical companies, Gland Pharma is using its existing factory capacity and regulatory credentials to create a more consistent stream of income, rather than relying solely on its own product launches.
Despite the positive outlook, investors should keep a close eye on execution risks. The success of this new deal depends entirely on a smooth two-year technology transfer process, which can face technical or operational delays. Like all major pharmaceutical manufacturers, Gland Pharma also faces the constant pressure of regulatory audits and quality compliance. If these processes run into issues, it could lead to project delays or increased costs. Additionally, while the US and European markets remain strong, the company has faced challenges in generating significant growth in its other international markets.
Looking ahead, the key monitorables for shareholders will be the progress of the technology transfer for this new partnership and the company's ability to maintain its margin levels as it grows its CDMO business. Investors will also watch how the company’s subsidiary, Cenexi, performs alongside the core business in the coming quarters to see if the overall growth trend remains stable.